Aurobindo Pharma was trading at RS 1223.60 on the BSE, up 6.80 points or 0.56% from its previous close of RS 1216.80.

The stock opened at RS 1216.80 and moved between an intraday high of RS 1226.25 and a low of RS 1216.80. A total of 1,999 shares were traded so far.

The BSE Group ‘A’ stock, with a face value of RS 1, has recorded a 52-week high of RS 1364.95 on January 2, 2025, and a 52-week low of RS 994.35 on April 7, 2025. Over the past week, the scrip touched a high of RS 1240.00 and a low of RS 1177.55. The company’s current market capitalisation stands at RS 71,174.33 crore.

Promoter shareholding in Aurobindo Pharma remains strong at 51.82%, while institutional investors hold 41.81% and non-institutional investors 6.38%.

In a key corporate development, Aurobindo Pharma’s wholly owned subsidiary Helix Healthcare B.V. has entered into a binding agreement on December 22, 2025, with Shandong Luoxin Pharmaceutical Group Stock Co., China, to acquire an additional 20% stake in Luoxin Aurovitas Pharma (Chengdu) Co., China. Luoxin Aurovitas is a 30:70 joint venture between Helix Healthcare and Shandong Luoxin.

The acquisition aims to expand manufacturing capacity and achieve economies of scale by adding two high-speed production lines to meet growing market demand. The cost of acquisition is $5.12 million.

Aurobindo Pharma is engaged in the manufacturing of pharmaceutical products and offers active pharmaceutical ingredients (APIs), intermediates, and generic formulations, including products such as astemizole, domperidone, and omeprazole. The company has a strong presence across anti-infective, oral and sterile antibiotics, pain management, and osteoporosis segments.